AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33402937 — intervention group
Group type: COMPARATOR
Intervention: Supine 0° HOBE
Number of subjects: 114
Study 33402937 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine 45° HOBE
Number of subjects: 114
Study 34510208 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk miRNAs (specifically miR-3126 and miR-3184)
Number of subjects: 44
Study 34510208 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfection of Caco-2 human intestinal cells with HM miRNAs
Number of subjects: 44
Study 34339476 — intervention group
Group type: EXPERIMENTAL
Intervention: Uveitis group
Number of subjects: 195125
Study 34339476 — intervention group
Group type: COMPARATOR
Intervention: Non-uveitis group
Number of subjects: 195125
Study 32493780 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/Rif Ultra (Ultra)
Number of subjects: 398
Study 32493780 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/Rif (Xpert)
Number of subjects: 398
Study 32718265 — intervention group
Group type: EXPERIMENTAL
Intervention: Various periodontal plastic surgery procedures
Number of subjects: 42
Study 32718265 — intervention group
Group type: EXPERIMENTAL
Intervention: No graft surgical approach
Number of subjects: 42
Study 32718265 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft tissue thickness (STT)
Number of subjects: 42
Study 33228533 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen starvation conditions
Number of subjects: 0
Study 36190391 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide 80 μg daily subcutaneous injections
Number of subjects: 228
Study 36190391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 34268617 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 20
Study 34268617 — intervention group
Group type: COMPARATOR
Intervention: Baseline/pre-ECT
Number of subjects: 20
Study 34268617 — intervention group
Group type: EXPERIMENTAL
Intervention: Telomerase activity
Number of subjects: 20
Study 32175752 — intervention group
Group type: EXPERIMENTAL
Intervention: OnTrack + Brief Motivational Intervention (BMI)
Number of subjects: 60
Study 32175752 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 60
Study 34667010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention practices (n=4) with multifaceted implementation intervention including practice reimbursement, audit of attendance, electronic prompts, patient reminders, and information leaflet.
Number of subjects: 158
Study 34667010 — intervention group
Group type: COMPARATOR
Intervention: Control practices (n=4) receiving usual care (wait-list control).
Number of subjects: 158
Study 32371654 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting-state functional connectivity (rsFC) between left middle temporal gyrus, left inferior parietal lobule, and left pulvinar
Number of subjects: 100
Study 32371654 — intervention group
Group type: EXPERIMENTAL
Intervention: New metrics assessing resting-state functional connectivity pattern similarity (rsFCS)
Number of subjects: 100
Study 32371654 — intervention group
Group type: EXPERIMENTAL
Intervention: Support vector regression based on left pulvinar connectivity patterns
Number of subjects: 100
Study 34183794 — intervention group
Group type: EXPERIMENTAL
Intervention: Lid wipes (LWs) containing terpinen‐4‐ol and sodium hyaluronate (Hy‐ter®)
Number of subjects: 48
Study 34183794 — intervention group
Group type: COMPARATOR
Intervention: Baby shampoo (BS)
Number of subjects: 48
Study 34183794 — intervention group
Group type: EXPERIMENTAL
Intervention: Lid wipes (LWs)
Number of subjects: 48
Study 34183794 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LWs and BS
Number of subjects: 48
Study 34099779 — intervention group
Group type: EXPERIMENTAL
Intervention: Populations of B. pendula on post-industrial wastelands
Number of subjects: 3
Study 34099779 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-lead heaps
Number of subjects: 3
Study 34099779 — intervention group
Group type: EXPERIMENTAL
Intervention: Soil parameters (potassium and phosphorus content)
Number of subjects: 3
Study 34099779 — intervention group
Group type: EXPERIMENTAL
Intervention: Seedlings from heaps (local gene resources)
Number of subjects: 3
Study 35682232 — intervention group
Group type: EXPERIMENTAL
Intervention: RNC + Exercise
Number of subjects: 27
Study 35682232 — intervention group
Group type: EXPERIMENTAL
Intervention: RNC
Number of subjects: 27
Study 35682232 — intervention group
Group type: COMPARATOR
Intervention: Usual nicotine cigarettes (Control)
Number of subjects: 27
Study 36287272 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish containing 22.600 fluoride ppm and tricalcium phosphate
Number of subjects: 58
Study 36287272 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assembling peptides
Number of subjects: 58
Study 36287272 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish
Number of subjects: 58
Study 34352943 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative CO2 fractional laser (ACFL) treatment
Number of subjects: 15
Study 34352943 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated scar)
Number of subjects: 15
Study 36192291 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESB)
Number of subjects: 90
Study 36192291 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (TPVB)
Number of subjects: 90
Study 36192291 — intervention group
Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block (SAPB)
Number of subjects: 90
Study 32401286 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT
Number of subjects: 204
Study 32401286 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face CBT
Number of subjects: 204
Study 32401286 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 204
Study 34607144 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (group E, n = 9)
Number of subjects: 27
Study 34607144 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin type A (BTX‐A, group B, n = 9)
Number of subjects: 27
Study 34607144 — intervention group
Group type: COMPARATOR
Intervention: Saline (group S, n = 9)
Number of subjects: 27
Study 33541330 — intervention group
Group type: EXPERIMENTAL
Intervention: SBS & CBL method
Number of subjects: 59
Study 33541330 — intervention group
Group type: COMPARATOR
Intervention: LBL & CBL method
Number of subjects: 59
Study 32069513 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet- and mobile-based interventions (IMIs)
Number of subjects: 0
Study 34983126 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant oral therapy with tadalafil 5 mg and L-arginine 2,500 mg
Number of subjects: 0
Study 34983126 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity extracorporeal shock wave therapy (Li-ESWT) alone
Number of subjects: 0
Study 34004347 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 225
Study 34004347 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Psychoeducation (EDU)
Number of subjects: 225
Study 34004347 — intervention group
Group type: COMPARATOR
Intervention: Usual Medical Care (UC)
Number of subjects: 225
Study 32471390 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized rehabilitation plan created with a dedicated research nurse based on an evidence‐based decision support tool.
Number of subjects: 0
Study 32471390 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 33736846 — intervention group
Group type: EXPERIMENTAL
Intervention: Forensic evidence (DNA, fingerprint)
Number of subjects: 0
Study 33736846 — intervention group
Group type: EXPERIMENTAL
Intervention: Forensic evidence (DNA)
Number of subjects: 0
Study 32050979 — intervention group
Group type: EXPERIMENTAL
Intervention: 'large-normal' portion size (747 kcal)
Number of subjects: 30
Study 32050979 — intervention group
Group type: EXPERIMENTAL
Intervention: 'small-normal' portion size (543 kcal)
Number of subjects: 30
Study 32050979 — intervention group
Group type: EXPERIMENTAL
Intervention: 'smaller than normal' portion size (339 kcal)
Number of subjects: 30
Study 32050979 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction to portion sizes
Number of subjects: 30
Study 35557376 — intervention group
Group type: COMPARATOR
Intervention: WALK (walking at 30% VO2 max for 30 min)
Number of subjects: 10
Study 35557376 — intervention group
Group type: EXPERIMENTAL
Intervention: WALK+COG (walking at 30% VO2 max for 30 min while completing N‐back cognitive tasks)
Number of subjects: 10
Study 33743199 — intervention group
Group type: EXPERIMENTAL
Intervention: BiOC service
Number of subjects: 1422
Study 33743199 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1422
Study 34239883 — intervention group
Group type: COMPARATOR
Intervention: Bilateral alternating CAM (CAMbi)
Number of subjects: 85
Study 34239883 — intervention group
Group type: COMPARATOR
Intervention: Unilateral CAM of the operated leg (CAMuni)
Number of subjects: 85
Study 34239883 — intervention group
Group type: COMPARATOR
Intervention: Both CAM groups (CAMuni and CAMbi)
Number of subjects: 85
Study 32088018 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rotavirus vaccine (RVV)
Number of subjects: 219
Study 32088018 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher length-for-age Z-score (LAZ) around the time of vaccination
Number of subjects: 219
Study 32088018 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent administration of OPV and RVV
Number of subjects: 219
Study 32088018 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher LAZ score post-vaccination
Number of subjects: 219
Study 32088018 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher birthweight
Number of subjects: 219
Study 35283046 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2000 IU/day)
Number of subjects: 248
Study 35283046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 35441470 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide 2.4 mg
Number of subjects: 1961
Study 35441470 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1961
Study 33992607 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (target dose of 400 mg daily)
Number of subjects: 52
Study 33992607 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (target dose of 40 mg daily)
Number of subjects: 52
Study 32138707 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife-led brief counseling intervention
Number of subjects: 90
Study 32138707 — intervention group
Group type: COMPARATOR
Intervention: Postnatal routine care (Control)
Number of subjects: 90
Study 35085831 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment T
Number of subjects: 0
Study 35085831 — intervention group
Group type: COMPARATOR
Intervention: Reference treatment R
Number of subjects: 0
Study 34793640 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination paracetamol iv (1 g) and ibuprofen iv (800 mg)
Number of subjects: 36
Study 34793640 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol iv only (1 g)
Number of subjects: 36
Study 34793640 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen iv only (800 mg)
Number of subjects: 36
Study 34793640 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination paracetamol iv and ibuprofen iv
Number of subjects: 36
Study 34793640 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol iv only
Number of subjects: 36
Study 34793640 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen iv only
Number of subjects: 36
Study 34077032 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant
Number of subjects: 0
Study 34077032 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 5 mg
Number of subjects: 0
Study 34077032 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Number of subjects: 0
Study 34077032 — intervention group
Group type: COMPARATOR
Intervention: Other hypnotics (indirect comparison)
Number of subjects: 0
Study 35751180 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified CARELINK programme (multicomponent intervention with 6 home-based sessions and 5 telephone calls)
Number of subjects: 119
Study 35751180 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified CARELINK programme (multicomponent intervention)
Number of subjects: 119
Study 35751180 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 119
Study 33545983 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block (FNB) with epidural anesthesia
Number of subjects: 41
Study 33545983 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia only (Control group)
Number of subjects: 41
Study 36107990 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training (AET)
Number of subjects: 73
Study 36107990 — intervention group
Group type: COMPARATOR
Intervention: Stretching and Toning (SAT)
Number of subjects: 73
Study 34820153 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender Aromatherapy (LA)
Number of subjects: 62
Study 34820153 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 62
Study 34467453 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadoxetic acid–enhanced MRI
Number of subjects: 359
Study 33857496 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate III (HM3)
Number of subjects: 569
Study 33857496 — intervention group
Group type: COMPARATOR
Intervention: Heartware HVAD
Number of subjects: 569
Study 34014472 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual counseling (3 sessions of group counseling)
Number of subjects: 56
Study 34014472 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 56
Study 32440977 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1% ophthalmic suspension
Number of subjects: 75
Study 32440977 — intervention group
Group type: COMPARATOR
Intervention: Bromfenac 0.09% ophthalmic solution
Number of subjects: 75
Study 35555888 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose oral FeSO4 (150-200 mg) for 8 weeks
Number of subjects: 0
Study 35555888 — intervention group
Group type: EXPERIMENTAL
Intervention: Heme-iron-polypeptide (HIP)
Number of subjects: 0
Study 35555888 — intervention group
Group type: COMPARATOR
Intervention: Control group (plasma from participants without obesity or bariatric surgery)
Number of subjects: 0
Study 33871211 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly 300 mg azathioprine (n = 40)
Number of subjects: 80
Study 33871211 — intervention group
Group type: COMPARATOR
Intervention: 15 mg methotrexate every week (n = 40)
Number of subjects: 80
Study 33871211 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 34493130 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation with Bifidobacterium Lactis BS01 and Lactobacillus Acidophilus LA02 for 6 weeks
Number of subjects: 53
Study 34493130 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 6 weeks
Number of subjects: 53
Study 33269889 — intervention group
Group type: EXPERIMENTAL
Intervention: Face Pain Scale
Number of subjects: 117
Study 33269889 — intervention group
Group type: COMPARATOR
Intervention: Borg Scale
Number of subjects: 117
Study 33400433 — intervention group
Group type: COMPARATOR
Intervention: Two injections from two planes (Group C)
Number of subjects: 70
Study 33400433 — intervention group
Group type: EXPERIMENTAL
Intervention: Two injections in one plane (Group E)
Number of subjects: 70
Study 32964512 — intervention group
Group type: EXPERIMENTAL
Intervention: Supersaturated calcium phosphate rinse
Number of subjects: 45
Study 32964512 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-soft toothbrush with control regimen
Number of subjects: 45
Study 32964512 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (0.12% chlorhexidine gluconate + 3% sodium bicarbonate + nystatin 5000 U/mL)
Number of subjects: 45
Study 35565911 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Weight (NW)
Number of subjects: 176
Study 35565911 — intervention group
Group type: EXPERIMENTAL
Intervention: Over Weight (OW)
Number of subjects: 176
Study 35565911 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (NW and OW)
Number of subjects: 176
Study 33326047 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C and growth factors (GFs)
Number of subjects: 149
Study 33326047 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C only
Number of subjects: 149
Study 33512013 — intervention group
Group type: EXPERIMENTAL
Intervention: ddPCR
Number of subjects: 90
Study 33512013 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-qPCR
Number of subjects: 90
Study 33512013 — intervention group
Group type: EXPERIMENTAL
Intervention: ddPCR and RT-qPCR
Number of subjects: 90
Study 33512013 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-qPCR and ddPCR
Number of subjects: 90
Study 35057578 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Number of subjects: 67
Study 35057578 — intervention group
Group type: COMPARATOR
Intervention: Traditional IBS diet
Number of subjects: 67
Study 32198861 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (20 mg/kg over 20 minutes)
Number of subjects: 110
Study 32198861 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (20 mg/kg over 20 minutes)
Number of subjects: 110
Study 32198861 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (20 mg/kg over 20 minutes)
Number of subjects: 110
Study 36031787 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/4‐inch soft plastazote (SP) flat insole
Number of subjects: 16
Study 36031787 — intervention group
Group type: EXPERIMENTAL
Intervention: Metatarsal pad positioned proximal to the metatarsal head (MTH) on the control insole (P0)
Number of subjects: 16
Study 36031787 — intervention group
Group type: EXPERIMENTAL
Intervention: Metatarsal pad positioned 10 mm distal from the proximal border of the MTH on the control insole (P10)
Number of subjects: 16
Study 36031787 — intervention group
Group type: COMPARATOR
Intervention: 1/16‐inch insole (control)
Number of subjects: 16
Study 32342846 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass testing and treatment (MTaT) of malaria infections, tested three times per year for two years, treated with dihydroartemisinin-piperaquine.
Number of subjects: 10
Study 32342846 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 clusters where MTaT was not implemented).
Number of subjects: 10
Study 32342846 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass testing and treatment (MTaT) of malaria infections.
Number of subjects: 10
Study 35999074 — intervention group
Group type: EXPERIMENTAL
Intervention: Size 2 GlideScope® blade
Number of subjects: 60
Study 35999074 — intervention group
Group type: COMPARATOR
Intervention: Size 1 GlideScope® blade
Number of subjects: 60
Study 36068131 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal therapy with TENS (12 sessions of 20 min, pulse: 200μs, frequency: 10Hz) followed by vocal exercises (30 min)
Number of subjects: 27
Study 36068131 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS (12 sessions of 20 min, same conditions as EG but without electric stimulus) followed by vocal exercises (30 min)
Number of subjects: 27
Study 36068131 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal therapy with TENS followed by vocal exercises
Number of subjects: 27
Study 36068131 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS followed by vocal exercises
Number of subjects: 27
Study 36068131 — intervention group
Group type: COMPARATOR
Intervention: Vocal therapy without TENS
Number of subjects: 27
Study 35584874 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted vaginal delivery
Number of subjects: 3594
Study 35584874 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery by caesarean section
Number of subjects: 3594
Study 35584874 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal health problems during childbirth
Number of subjects: 3594
Study 35584874 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm newborns
Number of subjects: 3594
Study 35584874 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborns moved slowly immediately after birth
Number of subjects: 3594
Study 35584874 — intervention group
Group type: EXPERIMENTAL
Intervention: Sick newborns
Number of subjects: 3594
Study 34190197 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA, systemic, repeated 1 g bolus
Number of subjects: 123
Study 34190197 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA, topically intra-articularly, 2 g in 50 mL saline
Number of subjects: 123
Study 34190197 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study 32774652 — intervention group
Group type: EXPERIMENTAL
Intervention: STOPBANG score at threshold 3
Number of subjects: 3033
Study 32774652 — intervention group
Group type: EXPERIMENTAL
Intervention: STOPBANG score
Number of subjects: 3033
Study 36472034 — intervention group
Group type: EXPERIMENTAL
Intervention: TQHXD‐CSF
Number of subjects: 0
Study 36472034 — intervention group
Group type: EXPERIMENTAL
Intervention: TQHXD‐CSF+si‐ASK1
Number of subjects: 0
Study 36472034 — intervention group
Group type: COMPARATOR
Intervention: OGD/R
Number of subjects: 0
Study 36472034 — intervention group
Group type: EXPERIMENTAL
Intervention: Z‐VAD‐FMK (20 μmol·L(‐1))
Number of subjects: 0
Study 36472034 — intervention group
Group type: EXPERIMENTAL
Intervention: si‐ASK1
Number of subjects: 0
Study 36472034 — intervention group
Group type: COMPARATOR
Intervention: Control group (blank cerebrospinal fluid)
Number of subjects: 0
Study 33200488 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg nanocurcumin daily for 12 weeks
Number of subjects: 60
Study 33200488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 37773192 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to post-doctoral researcher (n=151)
Number of subjects: 630
Study 37773192 — intervention group
Group type: COMPARATOR
Intervention: No exposure to post-doctoral researcher (n=164)
Number of subjects: 630
Study 37773192 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to supervisor (n=155)
Number of subjects: 630
Study 37773192 — intervention group
Group type: COMPARATOR
Intervention: No exposure to supervisor (n=160)
Number of subjects: 630
Study 34406619 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 2856
Study 34406619 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 2856